The prescription drug Onglyza is just one of several new kinds of treatments for patients with diabetes. The medications are DPP-4 drugs used to help stimulate insulin production after a meal. However, the makers of Onglyza, AstraZeneca, are facing several lawsuits alleging serious side effects from patients who have taken the drug.
Onglyza was approved by the FDA in 2009. It is a popular diabetes drug because it does not encourage weight gain like some other diabetes medications. The drug reached $786 million in sales in 2015.
However, some doctors are concerned about the increased risk of pancreatitis. Pancreatitis is an inflammation of the pancreas. There are also concerns about pancreatic and thyroid cancer being reported. Hundreds of patients who have developed pancreatitis or pancreatic cancer have filed lawsuits, claiming the manufacturer did not warn of these risks.
In April of 2015, the FDA decided that Onglyza needed to carry a warning about the increased risk of heart failure. Data from a SAVOR study indicated that patients taking the diabetes medication had a 27% risk of heart failure hospitalizations.
Additionally, a number of studies conducted in 2013 raised concerns about the DPP-4 drugs and their links to abnormal pre-cancerous cells in the pancreas. More recent studies, conducted in 2015, show a higher-than-normal risk pancreatic and thyroid cancer and heart failure.
If you have suffered serious injury or complications due to taking the prescribed drug Onglyza, you may be entitled to compensation. Contact the law offices of John Foy & Associates. The “Strong Arm” attorneys will help you get the compensation that you deserve. Contact us today.